|
UY38848A
|
|
SALT
|
|
WO2020196570A1
|
|
Pickling agent and processed meat product
|
|
WO2020100959A1
|
|
1,3,4-oxadiazolone compound and medicine
|
|
EP3815696A1
|
|
Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
|
|
KR20210008055A
|
|
Method for preparing oligonucleotide compounds
|
|
KR20210006437A
|
|
Azabenzimidazole compounds and medicines
|
|
WO2019177132A1
|
|
Orally disintegrating tablet
|
|
WO2019172175A1
|
|
Glycation inhibitor
|
|
WO2019172174A1
|
|
Food material having rage signaling inhibitory effect
|
|
SG11202007967YA
|
|
Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
|
|
GB201821269D0
|
|
Myostatin signal inhibitor
|
|
JP2019115339A
|
|
Meat-like emulsion composition and meat-like processed food
|
|
KR20200060418A
|
|
decision
|
|
BR112020005428A2
|
|
form-i crystal, form-ii crystal, pharmaceutical composition, pgi2 agonistic receptor, therapeutic agent comprising said crystals and use thereof
|
|
JP2019026640A
|
|
Muscle activator
|
|
WO2018147353A1
|
|
Tablet
|
|
CA3007577A1
|
|
Compression-molded preparation
|
|
SG11201804320QA
|
|
Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
|
|
EP3351634A1
|
|
Antisense nucleic acid for treating amyotrophy
|
|
EP3778895A1
|
|
Antisense nucleic acid
|
